

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 1

**ATTACHMENT B**  
**(Correct Copy of Claims Believed to be in Condition for Allowance)**

3. Colostrinin for use in the treatment of chronic disorders of the central nervous system.
4. Colostrinin according to claim 3, for use in the treatment of neurological disorders and/or mental disorders.
5. Colostrinin according to claim 3, for use in the treatment of dementia and/or neurodegenerative diseases.
6. Colostrinin according to claim 3, for use in the treatment of Alzheimer's disease and/or motor neurone disease.
7. Colostrinin according to claim 3, for use in the treatment of psychosis and/or neurosis.

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 2

9. Colostrinin for use in the treatment of chronic disorders of the immune system in humans.

10. Colostrinin according to claim 9, for use in the treatment of diseases with a bacterial and viral aetiology, and/or for use in the treatment of acquired immunological deficiencies.

11. Colostrinin according to claim 9, for use in the treatment of chronic bacterial and/or viral infections.

13. A medicament comprising Colostrinin for use in the treatment of chronic disorders of the central nervous system.

14. The medicament according to claim 13 for use in the treatment of neurological disorders and/or mental disorders.

15. The medicament according to claim 14 for use in the treatment of dementia and/or neurodegenerative diseases.

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 3

16. The medicament according to claim 14 for use in the treatment of Alzheimer's disease and/or motor neurone disease.

17. The medicament according to claim 14 for use in the treatment of psychosis and/or neurosis.

19. A medicament comprising Colostrinin for use in the treatment of chronic disorders of the immune system in humans.

20. The medicament according to claim 19 for use in the treatment of diseases with a bacterial and/or viral aetiology, and/or for use in the treatment of acquired immunological deficiencies.

21. The medicament according to claim 19 for use in the treatment of bacterial and/or viral infections.

22. The medicament according to claim 19 wherein said Colostrinin is non-ovine Colostrinin.

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 4

24. A method of treating disorders of the central nervous system and/or of the immune system, comprising administering a predetermined amount of a composition containing Colostrinin to a human patient for a predetermined period of time.

26. A method according to claim 24 wherein the Colostrinin is non-ovine Colostrinin.

27. A method according to claim 26, wherein said predetermined amount of Colostrinin is in the range of about 25 to 2000 micrograms.

28. A method according to claim 27, comprising a cycle of administering 25 to 2000 micrograms of Colostrinin each day to a patient for a first period, followed by a second period when no Colostrinin is administered.

29. A method according to claim 28, wherein the first period is in the range of about 2 to 4 weeks, and the second period is in the range of about 2 to 5 weeks.

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 5

30. A method according to claim 28, wherein the cycle is repeated at least once.

31. A pharmaceutical composition for humans comprising a preselected amount of Colostrinin in combination with a physiologically acceptable carrier.

32. A composition according to claim 31, wherein the Colostrinin is non-ovine Colostrinin.

33. A composition according to claim 31, in a form suitable for injection.

34. A composition according to claim 31, in a form suitable for absorption through the mucosa of the oral/nasopharyngeal cavity and/or in a form suitable for absorption in the alimentary canal.

35. A composition according to claim 31, in the form of a tablet, lozenge, gel, patch or plaster.

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 6

36. A composition according to claim 31, comprising 25 to 1000 micrograms of Colostrinin.

40. The use of Colostrinin as a dietary supplement for babies, small children, adults who have been subjected to chemotherapy and/or adults who have suffered from anorexia, or weight loss due to chronic disease.

41. A dietary supplement comprising an orally ingestible combination of Colostrinin in an isolated form in combination with a physiologically acceptable carrier.

44. The use of Colostrinin in the manufacture of a medicament for use in the stimulation and/or modulation of the immune system of humans.

46. A prophylactic medicament for humans comprising Colostrinin for use in preventing and/or inhibiting the development of Alzheimer's disease.

47. The use of Colostrinin in the manufacture of a prophylactic medicament for humans, to prevent or inhibit the development of Alzheimer's disease.

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 7

51. A nonapeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) for use as a medicament.

52. A nonapeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) for use in the manufacture of a medicament for treating chronic disorders of the immune system in humans.

53. The use of a nonapeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) in the manufacture of a medicament for treating chronic disorders of the central nervous system.

54. A pharmaceutical composition comprising a nonapeptide having the composition Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) in combination with a physiologically acceptable carrier.

55. A method of making a pharmaceutical composition comprising combining a nonapeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-

Applicants: Marin Janusz et al.  
Serial No. 09/269,845  
Confirmation No.: 1703  
Filing Date: 24-SEP-99  
Group Art Unit: 1653  
Attachment B - Page 8

Pro-Leu-Phe-Pro (SEQ ID NO:1) with a physiologically acceptable carrier, and forming said mixture into a form in which it can be administered to a patient.

56. A pharmaceutical composition in the form of an oral dosage comprising a preselected amount of Colostrinin in combination with a physiologically acceptable carrier.